ES2090177T3 - Derivados de pirrol. - Google Patents

Derivados de pirrol.

Info

Publication number
ES2090177T3
ES2090177T3 ES91111221T ES91111221T ES2090177T3 ES 2090177 T3 ES2090177 T3 ES 2090177T3 ES 91111221 T ES91111221 T ES 91111221T ES 91111221 T ES91111221 T ES 91111221T ES 2090177 T3 ES2090177 T3 ES 2090177T3
Authority
ES
Spain
Prior art keywords
pirrol
derivatives
hyperlipoproteinemia
hypercholesterolemia
hmg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91111221T
Other languages
English (en)
Inventor
Kentaro Hirai
Teruyuki Ishiba
Haruo Koike
Nasamichi Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of ES2090177T3 publication Critical patent/ES2090177T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LOS COMPUESTOS DE ESTA INVENCION INHIBEN LA REDUCTASA HMG-COA, Y POR LO TANTO SUPRIMEN LA SINTESIS DEL COLESTEROL. SON UTILES EN EL TRATAMIENTO DE LA HIPERCOLESTEROLEMIA, HIPERLIPOPROTEINEMIA Y ATEROSCLEROSIS.
ES91111221T 1990-07-05 1991-07-05 Derivados de pirrol. Expired - Lifetime ES2090177T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17856490 1990-07-05

Publications (1)

Publication Number Publication Date
ES2090177T3 true ES2090177T3 (es) 1996-10-16

Family

ID=16050690

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91111221T Expired - Lifetime ES2090177T3 (es) 1990-07-05 1991-07-05 Derivados de pirrol.

Country Status (10)

Country Link
US (1) US5128366A (es)
EP (1) EP0464845B1 (es)
JP (1) JP3068665B2 (es)
KR (1) KR0167781B1 (es)
AT (1) ATE138909T1 (es)
CA (1) CA2046146C (es)
DE (1) DE69119979T2 (es)
DK (1) DK0464845T3 (es)
ES (1) ES2090177T3 (es)
GR (1) GR3020689T3 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687146B1 (fr) * 1992-02-12 1994-04-01 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE4243279A1 (de) * 1992-12-21 1994-06-23 Bayer Ag Substituierte Triole
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6962999B2 (en) 2001-07-25 2005-11-08 Pharmacore, Inc. Process for preparing unsymmetrical biaryls and alkylated aromatic compounds from arylnitriles
SG147450A1 (en) * 2003-10-29 2008-11-28 Wyeth Corp Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
JP5173192B2 (ja) 2004-09-30 2013-03-27 武田薬品工業株式会社 プロトンポンプ阻害薬
US7977488B2 (en) 2005-08-30 2011-07-12 Takeda Pharmaceutical Company Limited 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
KR100856133B1 (ko) * 2008-01-11 2008-09-03 조동옥 아토르바스타틴의 개선된 제조방법
NZ591793A (en) 2008-08-27 2012-11-30 Takeda Pharmaceutical Substituted 1-(4-fluoro-5-(2-fluoropyridin-3-yl)-1-((pyrindin-2-yl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine compounds
CN111225672B (zh) 2017-10-16 2023-09-29 清华大学 甲羟戊酸通路抑制剂及其药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT48208A (en) * 1985-10-25 1989-05-29 Sandoz Ag Process for producing heterocyclic analogues of mevalolactone derivatives and pharmaceutical compositions comprising such compounds
NO881411L (no) * 1987-04-14 1988-10-17 Bayer Ag Substituerte pyrroler.
IT1215578B (it) * 1987-06-24 1990-02-14 Roussel Maestretti Spa Derivati di 1-arilsolfonil1,5-diidro 2h-pirrol 2-one, loro procedimento di preparazione e loro applicazione come sostanze medicinali.
DE3722806A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-hept-6-ensaeuren, 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-heptansaeuren, ihre entsprechenden (delta)-lactone und salze, verfahren zu ihrer herstellung ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis

Also Published As

Publication number Publication date
JP3068665B2 (ja) 2000-07-24
ATE138909T1 (de) 1996-06-15
US5128366A (en) 1992-07-07
GR3020689T3 (en) 1996-10-31
DK0464845T3 (da) 1996-06-24
KR920002536A (ko) 1992-02-28
EP0464845B1 (en) 1996-06-05
DE69119979D1 (de) 1996-07-11
CA2046146A1 (en) 1992-01-06
EP0464845A1 (en) 1992-01-08
CA2046146C (en) 1997-02-25
DE69119979T2 (de) 1996-10-24
JPH04352767A (ja) 1992-12-07
KR0167781B1 (ko) 1999-01-15

Similar Documents

Publication Publication Date Title
HU0004863D0 (es)
ES2188584T3 (es) Derivados heterociclicos de amina.
DE69925256D1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
NL970034I1 (nl) Trans-6-2-(3- of 4-carbonamido-gesubstitueerd pyrrool-1-yl)alkyl!-4-hydroxypyran-2-on als remmers van cholesterolsynthese.
AU9020591A (en) Method of treatment of waste paper or the like
AU7820491A (en) Substituted Phthalides and Heterocyclic Phthalides and derivatives thereof.
ES2090177T3 (es) Derivados de pirrol.
MX9702175A (es) Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
MX9303594A (es) Oximas piridino, pirrolidino y azepino substituidas utiles como agentes antiateroscleroticos y antihipercolesterolemicos.
AU3869895A (en) Azetidinone derivatives for the treatment of atherosclerosis
DE450812T1 (de) Antihypercholesterolemika.
AU4751800A (en) Pyrimidinones derivatives for the treatment of atherosclerosis
AU6305096A (en) Azetidinone derivatives for the treatment of atherosclerosis
NO984939D0 (no) Azetidinon-derivater for behandling av atherosklerose
GR880100332A (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΡΕΔΟΥΚΤΑΣΗΣ HMG-CοA ΠΟΥ ΠΕΡΙΕΧΕΙ ΦΩΣΦΟΡΟ,ΝΕΑ ΕΝΔΙΑΜΕΣΑ ΚΑΙ ΜΕΘΟΔΟΣ
DE69611758D1 (de) N-1-carbocylalkyl derivate von lsd
DE69103919D1 (de) Diaminoverbindungen und Vorstufe dafür.
IT1255470B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
NO923862L (no) Inhibitorer for hmg-coa-reduktase
FI904885A (fi) Registreringsanordning foer idrottsprestationer, speciellt foer haendelsefoerloppet i lagspel.
TR27040A (tr) Halojenlenmis alkeniltio sübstitüeli pirimidin bilesikleri.
AU5550990A (en) Novel hmg coa reductase inhibitors

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 464845

Country of ref document: ES

FG2A Definitive protection

Ref document number: 464845

Country of ref document: ES